Article
Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy - 1 Nov 2008
Moltó José, Santos José R, Pérez-Alvarez Nuria, Cedeño Samandhy, Miranda Cristina, Khoo Saye, Else Laura, Llibre Josep Maria, Valle Marta, Clotet Bonaventura
Abstract excerpt
The aim of this study was to evaluate the relationship between the virological response to darunavir-based salvage antiretroviral therapy and the darunavir genotypic and virtual inhibitory quotients (gIQ and vIQ, respectively). Thirty-seven HIV-infected patients failing protease inhibitor-based antiretroviral regimens who started salvage therapy containing darunavir-ritonavir were prospectively studied. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.